Continue to learn
Maxvax has received funding from the Bill & Melinda Gates Foundation to support the development of a low-cost HPV therapeutic vaccine candidate, aligning with global efforts to address the challenges posed by HPV infection that can lead to cervical cancer.
more >On April 18, 2023, the launching ceremony for Maxvax’s production platform for innovative vaccines was successfully held. The ceremony took place in the Life Science & Tech Park of Lingang Special Area, Shanghai. This marks that Maxvax is embarking on a new journey of commercializing its R&D achievements and demonstrates its determination and confidence to promote industrialization.
more >On September 13th, 2023, the Global Health Vaccine Adjuvant Webinar, which was hosted by Global Vaccine and Immunization Research Forum (GVIRF), was successfully held. Maxvax was the only innovative vaccine company in China that was invited to attend the virtual seminar. On the meeting, Maxvax’s founder and CEO Dr. Dexiang Chen gave a presentation on Enhancing Public Health Capacity: Strengthening the Global Availability, Accessibility, and Affordability of Adjuvants and Formulations, and took part in the keynote discussion.
more >On January 08, 2023, the enrollment was initiated for Phase II clinical study for recombinant rotavirus subunit vaccine independently developed by MAXVAX Biotechnology Limited Liability Company (hereinafter referred to as "Maxvax Biotech"). Despite that the clinical study was repeatedly postponed due to various factors at the end of last year, Maxvax Biotech and the investigators seized the "window period" together with the study sites - Henan Provincial Center for Disease Control and Prevention, Ningling County Center for Disease Control and Prevention, and Shangqiu Liangyuan District Center for Disease Control and Prevention - to overcome difficulties such as
more >On May 6, 2023, the kick-off meeting for the Phase II clinical study of Maxvax’s Recombinant Herpes Zoster Vaccine (CHO Cell) Biotechnology was successfully held in China’s northern province of Henan, and the enrollment was scheduled to be initiated on the next day.
more >Maxvax Biotech's new pipeline started the enrollment for clinical study and set another milestone in this year, standing forefront in the industry and achieving accelerated development.
more >
Maxvax has received funding from the Bill & Melinda Gates Foundation to support the development of a low-cost HPV therapeutic vaccine candidate, aligning with global efforts to address the challenges posed by HPV infection that can lead to cervical cancer.
more >
On September 13th, 2023, the Global Health Vaccine Adjuvant Webinar, which was hosted by Global Vaccine and Immunization Research Forum (GVIRF), was successfully held. Maxvax was the only innovative vaccine company in China that was invited to attend the virtual seminar. On the meeting, Maxvax’s founder and CEO Dr. Dexiang Chen gave a presentation on Enhancing Public Health Capacity: Strengthening the Global Availability, Accessibility, and Affordability of Adjuvants and Formulations, and took part in the keynote discussion.
more >
On May 6, 2023, the kick-off meeting for the Phase II clinical study of Maxvax’s Recombinant Herpes Zoster Vaccine (CHO Cell) Biotechnology was successfully held in China’s northern province of Henan, and the enrollment was scheduled to be initiated on the next day.
more >
On April 18, 2023, the launching ceremony for Maxvax’s production platform for innovative vaccines was successfully held. The ceremony took place in the Life Science & Tech Park of Lingang Special Area, Shanghai. This marks that Maxvax is embarking on a new journey of commercializing its R&D achievements and demonstrates its determination and confidence to promote industrialization.
more >
On January 08, 2023, the enrollment was initiated for Phase II clinical study for recombinant rotavirus subunit vaccine independently developed by MAXVAX Biotechnology Limited Liability Company (hereinafter referred to as "Maxvax Biotech"). Despite that the clinical study was repeatedly postponed due to various factors at the end of last year, Maxvax Biotech and the investigators seized the "window period" together with the study sites - Henan Provincial Center for Disease Control and Prevention, Ningling County Center for Disease Control and Prevention, and Shangqiu Liangyuan District Center for Disease Control and Prevention - to overcome difficulties such as
more >
Maxvax Biotech's new pipeline started the enrollment for clinical study and set another milestone in this year, standing forefront in the industry and achieving accelerated development.
more >